Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IQWiG’s Nods To Boehringer’s Giotrif and Novartis’ Ultibro Raise Submission Strategy Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s IQWiG has cleared Boehringer’s Giotrif for lung cancer and Novartis’ Ultibro Breezhaler for COPD, raising questions as to what HTA submission strategy drugs firms should adopt.

You may also be interested in...

Breo Coverage Gaining Ground, GSK’s Witty Assures Investors

GlaxoSmithKline’s COPD drug Breo Ellipta is facing reimbursement challenges, particularly in terms of Medicare Part D coverage. But CEO Andrew Witty told investors during a year-end sales and earnings call Feb. 5 that coverage is increasing and will continue to grow through 2014.

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

EMA Acts To Freeze GVK Drugs, Guard Against Shortages

The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts